Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: J Clin Pharmacol. 2014 Jan 17;54(6):682–687. doi: 10.1002/jcph.254

Figure 2.

Figure 2

Repeated measures linear modeling was used on (A) sVEGFR2 and (B) Ang2 concentrations, a test of the within subject change over time of exposure to sorafenib was performed using a Greenhouse-Geisser adjustment to derive the P-value (P ≤ 0.05 for both sVEGFR2 and Ang2). Dotted line indicates trend line in both A and B. sVEGFR2 concentrations clearly decline on exposure to sorafenib more than its regular fluctuation in healthy volunteers. Ang2 concentrations increased, but within its regular fluctuation found in healthy volunteers.